Recognition of Serious Bacterial Infections (Sepsis, Meningitis, and Urinary Tract Infection) in Febrile Infants Presenting to the Emergency Department: A Systematic Review of Clinical Prediction Rules
DOI:
https://doi.org/10.65759/5wx65j72Keywords:
Febrile infant, Serious bacterial infection, Invasive bacterial infection, Clinical prediction rule, ProcalcitoninAbstract
Background: Fever in infants aged 90 days or younger often leads to lumbar puncture, hospital admission and empirical antibiotics, although only a minority of these infants have a serious bacterial infection (SBI). Clinical prediction rules were developed to separate low-risk infants from those who need a full evaluation. Objective: To synthesize evidence on how well clinical prediction rules identify SBI and invasive bacterial infection (IBI) in febrile infants presenting to the emergency department. Methods: This systematic review followed the PRISMA 2020 statement. Two authors independently searched PubMed, Scopus, Web of Science and the Cochrane Library from inception to 31 May 2026. They screened records, extracted data and assessed risk of bias with QUADAS-2. Eligible studies derived or validated a prediction rule in febrile infants aged ≤90 days and reported accuracy against culture-confirmed SBI or IBI. Narrative synthesis was used because the studies were heterogeneous. Results: Ten studies met the inclusion criteria. Together they covered more than 17,000 infant evaluations, with partial overlap between cohorts. Rules combining urinalysis, absolute neutrophil count and procalcitonin gave the best balance of sensitivity and specificity: sensitivity was 92.0-97.7% and negative predictive value was above 99%. The updated PECARN rule kept 94.2% sensitivity in neonates and missed no case of meningitis. Used without procalcitonin, the American Academy of Pediatrics algorithm reached sensitivity of 88.9-100%, with specificity of 0-40.4%. Point-based rules and rules without procalcitonin showed lower specificity. Conclusion: Rules based on procalcitonin reliably identify febrile infants at low risk. External validation in neonates and in resource-limited settings is still limited.
References
1. Powell EC, Mahajan PV, Roosevelt G, Hoyle JD Jr, Gattu R, Cruz AT, et al. Epidemiology of bacterial infections in febrile infants aged 60 days and younger. Ann Emerg Med. 2018;71(2):211-216.
2. Biondi EA, Lee B, Ralston SL, Winikor JM, Lynn JF, Dixon A, et al. Prevalence of bacteremia and bacterial meningitis in febrile neonates and infants in the second month of life: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(3):e190874.
3. Greenhow TL, Hung YY, Herz AM. Changing epidemiology of bacteremia in infants aged 1 week to 3 months. Pediatrics. 2012;129(3):e590-e596.
4. Jaskiewicz JA, McCarthy CA, Richardson AC, White KC, Fisher DJ, Dagan R, et al. Febrile infants at low risk for serious bacterial infection—an appraisal of the Rochester criteria and implications for management. Pediatrics. 1994;94(3):390-396.
5. Huppler AR, Eickhoff JC, Wald ER. Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature. Pediatrics. 2010;125(2):228-233.
6. Cruz AT, Mahajan P, Bonsu BK, Bennett JE, Levine DA, Alpern ER, et al. Accuracy of complete blood cell counts to identify febrile infants 60 days or younger with invasive bacterial infections. JAMA Pediatr. 2017;171(11):e172927.
7. Pantell RH, Roberts KB, Adams WG, Dreyer BP, Kuppermann N, O'Leary ST, et al. Evaluation and management of well-appearing febrile infants 8 to 60 days old. Pediatrics. 2021;148(2):e2021052228.
8. Gomez B, Mintegi S, Bressan S, Da Dalt L, Gervaix A, Lacroix L; European Group for Validation of the Step-by-Step Approach. Validation of the "Step-by-Step" approach in the management of young febrile infants. Pediatrics. 2016;138(2):e20154381.
9. de Vos-Kerkhof E, Gomez B, Milcent K, Steyerberg EW, Nijman RG, Smit FJ, et al. Clinical prediction models for young febrile infants at the emergency department: an international validation study. Arch Dis Child. 2018;103(11):1033-1041.
10. Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tunik MG, et al. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infections. JAMA Pediatr. 2019;173(4):342-351.
11. Aronson PL, Shabanova V, Shapiro ED, Wang ME, Nigrovic LE, Pruitt CM, et al. A prediction model to identify febrile infants ≤60 days at low risk of invasive bacterial infection. Pediatrics. 2019;144(1):e20183604.
12. Velasco R, Gomez B, Benito J, Mintegi S. Accuracy of PECARN rule for predicting serious bacterial infection in infants with fever without a source. Arch Dis Child. 2021;106(2):143-148.
13. Nguyen THP, Young BR, Ballard DW, Greenhow TL, Vinson DR, Mark DG, et al. Using AAP guidelines for managing febrile infants without C-reactive protein and procalcitonin. Pediatrics. 2023;151(1):e2022058495.
14. Umana E, Mills C, Norman-Bruce H, Mitchell H, McFetridge L, Lynn F, et al. Performance of clinical decision aids (CDA) for the care of young febrile infants: a multicentre prospective cohort study conducted in the UK and Ireland. EClinicalMedicine. 2024;78:102961.
15. Burstein B, Wolek C, et al. Optimizing management of febrile young infants without serum procalcitonin. Pediatrics. 2025;155(2):e2024068200.
16. Aronson PL, Mahajan P, Meeks HD, et al. Prediction rule to identify febrile infants 61-90 days at low risk for invasive bacterial infections. Pediatrics. 2025;156(3):e2025071666.
17. Burstein B, Waterfield T, Umana E, Xie J, Kuppermann N. Prediction of bacteremia and bacterial meningitis among febrile infants aged 28 days or younger. JAMA. 2026;335(5):425-433.
18. Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr. 1992;120(1):22-27.
19. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. N Engl J Med. 1993;329(20):1437-1441.
20. Gomez B, Bressan S, Mintegi S, Da Dalt L, Blazquez D, Olaciregui I, et al. Diagnostic value of procalcitonin in well-appearing young febrile infants. Pediatrics. 2012;130(5):815-822.
21. Milcent K, Faesch S, Gras-Le Guen C, Dubos F, Poulalhon C, Badier I, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr. 2016;170(1):62-69.
22. Mintegi S, Bressan S, Gomez B, Da Dalt L, Blázquez D, Olaciregui I, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. Emerg Med J. 2014;31(e1):e19-e24.
23. Galetto-Lacour A, Zamora SA, Andreola B, Bressan S, Lacroix L, Da Dalt L, et al. Validation of a laboratory risk index score for the identification of severe bacterial infection in children with fever without source. Arch Dis Child. 2010;95(12):968-973.
24. Mahajan P, Kuppermann N, Mejias A, Suarez N, Chaussabel D, Casper TC, et al. Association of RNA biosignatures with bacterial infections in febrile infants aged 60 days or younger. JAMA. 2016;316(8):846-857.
